'
DBT smartphone app implemented by private clinic in Denmark

DBT smartphone app implemented by private clinic in Denmark

DBT smartphone app by Monsenso will be implemented by the end of August

Copenhagen, Denmark – 18 July 2017 Monsenso, a Danish developer in mobile health solutions for mental health, has announced that Datlinien, a private clinic in Denmark, will soon implement the Monsenso mHealth solution with an added Dialectical Behavioural Therapy (DBT) module.
DBT is an evidence-based treatment that is commonly used to treat Borderline Personality Disorder.

Online-based DBT solutions have been found to make treatment easier to manage for clinicians, by storing information in an easily accessible place through cloud technology.

A new DBT module was recently added to the Monsenso mHealth solution as part of the mDiary Study, a research project done in collaboration with several Danish partners. The Monsenso mHealth solution, which consists of a smartphone app for individuals and a web portal for clinicians, provides a reliable, efficient, and clinically-validated smartphone based approach to DBT.

Some of the key factors of DBT include skills training and self-monitoring, which have been administered traditionally through paper-based self-assessments, workbooks and diaries. The Monsenso DBT smartphone app helps optimise and organise this process, by putting self-assessments, self-monitoring, skills training, emotion rating, and synchronized clinician feedback into one convenient location – your smartphone.

Datlinien offers mental health services, with a special focus on DBT, to public and private institutions, and they provide DBT treatment for both group and individual therapy.

Thomas Lethenborg, CEO at Monsenso, said “This new DBT module was developed as part of the mDiary Study to complement the treatment of individuals undergoing DBT treatment. It was designed to modernise the traditionally used paper-based assessments and skills training, and to make it more intuitive.”

Dr. Shahram Elahi Panah, General Manager of Datlinien, said “By adopting this new technology, we want to raise the bar on the mental health services offered by private clinics in Denmark. The Monsenso DBT smartphone app makes data collection and skills training more fun and interactive, which is great for the patients because it increases compliance and engagement. On the other hand, it is also great for us, the clinicians, because we can visualise all the patient data more easily.”

Click on the link to read the press release in Danish.

For additional information contact:

Helen Chen
Marketing
Monsenso
+45 30 25 15 26
chen@monsenso.com

The IMPACHS project funded by Eurostars is ready to start

The IMPACHS project funded by Eurostars is ready to start

Copenhagen, Denmark – 28 June 2017.  The IMPACHS project funded by Eureka/Eurostars and the Innovation Fund in Demark, has the aim to design, develop and provide clinical evidence for the use of smartphone-based intervention technology for outpatients diagnosed with schizophrenia, to improve the availability and cost-effectiveness of mental healthcare.

The project, with a duration of 24 months (June 2017 – June 2019) and a total budget of 1.2 million Euros, brings together leading European research/academic institutions and SMEs.

The IMPACHS project (IMProving Availability and Cost-effectiveness of mental Healthcare for Schizophrenia through mHealth), is done in collaboration between Monsenso, the Psychiatric Research Unit from Region Zealand, time4you, and the University of Hamburg.

Cognitive Behavioural Therapy (CBT) is one of the most effective psychological approaches for psychotic symptom reduction, but only 10% of patients receive it due to growing shortage of professionals [1]. Mobile-based CBT interventions (mCBT), as an adjunct to traditional care, provide a unique opportunity to deliver continuous, cost-effective, accessible, non-stigmatizing and timely support to these patients[2], promoting the detection of alarming symptoms and reducing the duration of relapses, observed in 80% of patients[3].

The IMPACHS project aims to develop mobile- and context-aware CBT content, deployed through the time4you IBT® SERVER (eLearning) platform integrated into the Monsenso Clinic mHealth solution for mental illnesses that is HIPAA compliant and has a class 1 CE & TGA mark.

The staff at the University of Hamburg have extensive knowledge on using CBT for individuals with schizophrenia and has published several research papers in medical journals related to schizophrenia.  The project will leverage their substantial experience in clinical research within schizophrenia to develop the assessments and interventions planned.

The Psychiatric Research Unit of the Zealand Region of Denmark will begin the trial using an improved version of the Monsenso Clinic that offers psycho-education through the integrated IBT e-learning platform that delivers continuous, cost-effective, and timely support to individuals with schizophrenia, complementing their therapy.

Personalised triggers, defined jointly by individuals and therapists based on a person’s behaviours, can be used to detect symptom aggravation in real-time. Mobile CBT can help lower the severity of a person’s symptoms if the content is personalised and disorder-specific.

The objective of the clinical trial is to determine the feasibility of context-aware CBT and psycho-educative content in the users’ recovery process.

With regards to the clinical trial, Thomas Lethenborg, CEO at Monsenso, commented, “Mobile-based CBT and psychoeducation is a cost-efficient solution to complement a person’s treatment. In some cases, it might be the only type of therapy that some people might be able to access, depending on the waiting list for the mental health services, and their financial or geographical situation. This type of solution may be the best way to reach more people at a lower cost.”

Dr. Hartwig Holzapfel, Director of Professional Services, said “IMPACHS opens new ways for outpatient psychotherapy and patient education. With new individualized solutions that include learning analytics and adaptive learning, patients are empowered and gain faster access and better education. Mobile Health solutions are an economical and cost-efficient way of treatment and form an important building block of modern healthcare. Within the IMPACHS-project, time4you is responsible for the technical solution based on the IBT SERVER-software, system integration, and supports partners in developing content with methodical, didactical, medical and technical expertise.”

Click on the links to read the press release in Danish

[1] Bucci et al (2015) Using mobile technology to deliver a cognitive behaviour therapy-informed intervention in early psychosis (Actissist): study protocol for a randomised controlled trial. Trials 16:404

[2] Alvarez-Jimenez et al (2014) Online, social media and mobile technologies for psychosis treatment: A systematic review on novel user-led interventions. Schizophrenia Research 156 (2014) 96–106

[3] NICE Guidelines. Psychosis and schizophrenia in adults: treatment and management, [CG178]. London: Excellence NIfHaC; 2014.

For additional information contact:

Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 30 25 15 26
highland@monsenso.com

Axel Wolpert
Senior Consultant
time4you
+49 172 208 43 58
wolpert@time4you.de

Monsenso is a finalist for “Best eHealth solutions in Europe”

Monsenso is a finalist for “Best eHealth solutions in Europe”

Copenhagen, Denmark 21 April 2017Monsenso is a finalist for Best eHealth solutions in Europe. The Danish technology company developing mHealth solutions for mental health, was shortlisted for the Champions category. Of the 15 companies who applied in the same category, five of them were shortlisted to win the sought-after prize, which is organised by TICBioMed, with the objective to provide support for SMEs’ business success, offering a path to increase visibility and marketing opportunities to attract customers, partners and external capital.

Thomas Lethenborg, CEO at Monsenso, said, “This nomination for Best eHealth solutions in Europe is an extension of Monsenso’s growing success, driven by our commitment to establish Monsenso as an innovation leader in mHealth solutions for mental health.”

“Our efforts are underpinned by an excellent and dedicated team. The eHealth Competition is a coveted award among eHealth SMEs in Europe. The award recognises the innovation, social, demographic and economic impact of healthcare solutions, and we would like to congratulate all the finalists for their remarkable achievements,” added Mr. Lethenborg.

The finalists for the Competition of Best eHealth solutions in Europe will present their solution to the judging panel and over 700 delegates and speakers at Health 2.0, which showcases the latest innovations in healthcare, and is taking place from 3-5 May in Barcelona, Spain. The winner will be announced during the opening ceremony in Barcelona.

The Monsenso mHealth solution has been technically and clinically validated in clinical evaluation studies and randomised clinical trials (RCTs) and has a class 1 medical device CE Mark and a TGA Certification. Monsenso also holds an ISO 13485 certification, and is expected to obtain the ISO 27001 certification and become HIPAA compliant before the end of the year.

To read this press release in Danish click here.

For additional information contact:

Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 75 80 01
highland@monsenso.com

Monsenso partners with Gen Re to bring mHealth solution to insurance

Monsenso partners with Gen Re to bring mHealth solution to insurance

Copenhagen, Denmark – 19 April 2017. Monsenso, a Copenhagen-based technology company developing mHealth solutions for mental health, today announced a partnership with Gen Re, one of the world’s leading reinsurance companies. The objective of the partnership is to help insurance companies take advantage of Monsenso’s mHealth solution, which can assist in the prevention, early intervention and treatment of mental illness.

The Monsenso mHealth solution provides practical care to people with behavioural disorders, and has the potential to improve the prevention and management of disability claims.

Patient surveys reveal that mHealth technology increases an individual’s desire to play a more active role in their treatment. With the Monsenso mHealth solution, individuals can self-monitor their lifestyle and their symptoms, helping them recover faster from mental illness.

Gen Re delivers reinsurance solutions to the Life/Health and Property/Casualty insurance industries. With $14 billion in capital and approx. $6 billion in premiums, it is one of the leading reinsurers in the world with a global network of offices in key reinsurance markets.

Gen Re and Monsenso will work together to help insurance companies offer an enhanced service to their customers, and reduce costs in the process. By offering the solution, insurers can actively help their customers return to work more quickly, and avoid becoming ill again

Thomas Lethenborg, CEO at Monsenso, said, “The objective of this partnership is to promote the use of mHealth technology among insurance companies.  With this technology, their customers can get better faster by receiving better mental health care, while reducing costs at the same time.”

“Monsenso is looking to build sustainable, long-term partnerships, with the ultimate goal of delivering better care, to more people, at a lower cost,” added Mr. Lethenborg.

With a desire to bring the best innovative new technology solutions to their clients, Gen Re bring their extensive insurance industry knowledge to the partnership.

Jules Constantinou, Regional Manager, Gen Re Life/Health UK & Ireland, said, “ It is important that the life insurance industry embrace new technologies and new processes in order to remain relevant in the lives of customers going forward. Clinical medicine is also evolving and we are very pleased to announce this partnership with Monsenso, which should improve outcomes for insurance claimants who are battling mental illness”.

“We anticipate working closely with Monsenso to find solutions for Gen Re’s insurance clients and their customers worldwide” added Mr. Constantinou.

With its origins at the IT University of Copenhagen, the Monsenso mHealth solution for mental illnesses holds a CE Mark and a TGA certification. It is currently being used in a clinical capacity in the UK, Denmark, Norway, Sweden, Germany and Australia to support the treatment of a wide range of mental and behavioural disorders.

Click here to view the EnglishDanish and German version of the press release.

For additional information contact:

Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 75 80 01
highland@monsenso.com

Ross Campbell
Chief Underwriter
Life/Health Research & Development
Gen Re, UK
+ 44 (0)207 426 1803
ross_campbell@genre.com

About Gen Re
Gen Re delivers reinsurance solutions to the Life/Health and Property/Casualty insurance industries. We work closely with our clients to understand their strategic and operational goals, offering a wide range of products, tools and resources that aim to promote our clients’ ongoing growth and success. As a direct reinsurer, we are in the risk assumption business, just like our clients. Our shared perspective helps us understand and evaluate even the toughest risks – and propose the right solutions. Gen Re is a member of the Berkshire Hathaway family of companies, and has earned superior financial strength ratings from each of the major rating agencies.  To learn more visit:  www.genre.com

Eurostars grants Monsenso major funding for further development

Eurostars grants Monsenso major funding for further development

Copenhagen, Denmark – 31 January 2017. Monsenso ApS, Region Zealand, and two German partners have been granted major funding by Eureka/Eurostars, for the “IMProving Availability and Cost-effectiveness of mental Healthcare for Schizophrenia through mHealth” (IMPACHS) project.

The objective of the IMPACHS project is to design and develop a mobile and context-aware Cognitive Behaviour Therapy (CBT) content integrated into Monsenso Clinic. Through IMPACHS, Monsenso will deliver smartphone-based intervention technology for outpatients diagnosed with schizophrenia, to improve the availability and cost-effectiveness of mental health care.

Eurostars is the largest programme of knowledge-intensive SMEs with the objective of stimulating growth through international cooperation on the development of new products and services.

With regards to the grant, Thomas Lethenborg, CEO at Monsenso said “This grant will allow us to shift from being a remote patient monitoring digital tool to providing intelligent treatment to individuals with schizophrenia and other mental disorders over time. This will be the third project where we work on a similar solution since RADMIS  and ENTER (previously called E-Mental) have similar goals, but for patients with bipolar disorder and borderline personality disorder respectively.”

The programme is a jointly funded initiative between the EU and 36 Eurostars countries in Europe and around the world, including Canada, South Korea, South Africa, Turkey, and Israel. During the first round of qualifications, there were 370 submissions, from which 61 projects were from Denmark. When the final qualification round took place, 19 Danish projects were selected to receive significant funding.

The Danish Innovations Fund is the local representative of Eureka/Eurostars in Denmark, and its total budget to distribute amongst all Danish projects is 43 million DKK.

For additional information contact:

Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 75 80 01
highland@monsenso.com

To read the original press release in Danish issues by the Danish Innovations Fund, click here.

Private Swedish psychiatric clinic adopts mHealth solution for depression treatment

Private Swedish psychiatric clinic adopts mHealth solution for depression treatment

Copenhagen, Denmark – 13 December 2016. Monsenso, an innovation leader in mobile health (mHealth) technology for mental health, announced today that Psykiatriresurs, a private practice clinic in Gothenburg, Sweden, will implement the Monsenso mHealth solution for depression treatment.

The private clinic, which offers psychological and neuropsychiatric services, provides mental health treatment to 600 individuals with depression, anxiety, personality disorders and ADHD. In addition to these patients,  Psykiatriresurs will soon open a second clinic with a similar capacity, in Varberg, 80 km South of Gothenburg.

To start with, the mHealth solution for depression will be used by 250 patients, although Dr. Kristoffer Södersten, Director of the clinic, has plans to roll it out to all patients across both clinics.

“With this new technology, we want to raise the bar on the mental health treatment offered around the different private clinics in Sweden, and with the Monsenso mHealth solution we will be able to go a step further by reaching out to our patients when they need it the most. At  Psykiatriresurs  we are constantly looking to improve our patients’ experience, and our aim is to use the technology to improve and personalise even more of the treatments we currently provide to our patients,” said Dr. Södersten.

The mHealth solution for depression will be used by the clinicians to support the personalised treatment of individuals with this disorder. With the web portal, they will be able to identify the triggers and early-warning signs of all patients and schedule emergency consultations when needed.

Thomas Lethenborg, CEO at Monsenso, said “With the implementation of the Monsenso mHealth solution for depression, clinicians at  Psykiatriresurs  will have access to real-time patient monitoring and their patients’ historical data, which will help them make better decisions in regards to clinical treatment.”

Patients will use a smartphone app to collect sensor data and fill in routine self-assessments that reveal their current state of mind. The smartphone app also works as a self-management tool that allows patients to manage their symptoms.

Clinicians will use a web portal where they can access all the data collected by the patients’ smartphones, anytime, anywhere. The web portal enables clinicians to view relevant information related to each patient.

For additional information contact:

Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 75 80 01
highland@monsenso.com


Kristoffer Södersten

Director
Psykiatriresurs
+46 03 13 13 51 90
kristoffer.sodersten@psykiatriresursigoteborg.se   

You can download this article as a PDF in EnglishDanish and Swedish